POC Test Based on Quantum Dots Detects Antibody Responses
|
By LabMedica International staff writers Posted on 31 Oct 2019 |
|
Image: The Holomics Reader HRDR-300 mobile device was used to measure fluorescent intensity of the quantum dots complex after lateral migration of patient serum (Photo courtesy of Medical College of Georgia).
Point-of-care (POC) assays, which can be performed at or near the site of care with a rapid turnaround time, are pivotal to transforming global disease control efforts, particularly in resource-constrained settings where access to laboratory facilities is limited.
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Gold Member
Platelet Function Analyzer
PL-12
Latest Microbiology News
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
Molecular Diagnostics
view channel
Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
Molecular laboratories are under pressure to detect extremely low levels of residual disease, yet pre-analytical recovery of cell-free and genomic DNA from large-volume blood and plasma remains a persistent... Read more
New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
Plasma-based liquid biopsy can miss clinically actionable tumor signals, particularly in early-stage disease and low-shedding tumors, limiting its utility for routine monitoring. Clinical laboratories... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Pathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
